Skip to content

Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage

Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage in High-risk Patients in Sohag University Hospital: A Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05479357
Enrollment
80
Registered
2022-07-29
Start date
2022-07-28
Completion date
2022-12-30
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atonic Postpartum Hemorrhage, High Risk Pregnancy

Keywords

Atonic Postpartum Hemorrhage, Carbetocin, Oxytocin, High Risk Pregnancy

Brief summary

Comparison between Carbetocin and Oxytocin as prophylaxis against Primary Postpartum Hemorrhage.

Detailed description

Patients will be allocated randomly by simple randomization into either 1- the control group which will be given 10 IU oxytocin intravenously, OR 2- the treatment group which will be given 100 micrograms of carbetocin intravenously. The trial will be conducted on patients with high risk of developing atonic primary postpartum hemorrhage. The trial will be single blinded. All patients fulfilling the inclusion criteria undergoing elective Caesarean section will be approached by the treating physician and will be asked to participate in the study. An informed written consent will be taken from each patient. The data collected will include base line characteristics such as age, parity, body mass index, the risk for Postpartum hemorrhage in each patient, amount of blood loss, blood units given, complete blood picture (pre and post operative) and coagulation profile.

Interventions

DRUGOxytocin

10 iu will be given intravenously.

DRUGCarbetocin

100 micrograms will be given intravenously.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Masking description

Patient will be blinded to the drug to be used

Intervention model description

Randomized Clinical Trial (Simple randomization)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* • High risk patients for post-partum hemorrhage who will subjected to Caeserean section either elective or in labour at or after 36 weeks of gestation. This should include one or more of the following: 1. History of postpartum hemorrhage. 2. Delivery of a macrosomic baby (\> 4000 g). 3. Multiple gestation. 4. Polyhydramnios. 5. Grand Multiparity. 6. Interstitial or submucous fibroid. (Single larger than 4 cm or Multiple myomata) 7. Chorioamnionitis.

Exclusion criteria

* • Patients without high risk for post-partum hemorrhage. * Patients at high risk for postpartum hemorrhage but will deliver vaginally. * Patients with medical disorders complicating pregnancy. * Patients with coagulation defects. * Preterm pregnancies.

Design outcomes

Primary

MeasureTime frameDescription
Amount of Postpartum HemorrhageFirst 24 hours after DeliveryAmount of Blood Loss in milliliters. Pre-operative patient's Hemoglobin (Hb) level and 24 hours post-operative will be assessed to quantify amount of blood loss. Additionally, all towels prepared for CS will weighed, and the weight will be marked on each pack before autoclaving. All towels (used and unused) will be weighed again after use, and a difference of 1 gm will be considered as equivalent to 1 mL of absorbed blood.

Contacts

Primary ContactEman M Sabry, MBBCh
emanmahmoud@med.sohag.edu.eg+201012733125
Backup ContactAmr O Abdelkareem, MD
AMR.OTH@med.sohag.edu.eg+201001259562

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026